Cargando…
The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment
BACKGROUND: Escherichia coli (E. coli) is a common pathogen in bloodstream infections (BSI), and the production of extended-spectrum beta-lactamases (ESBLs) is its main mechanism of resistance. However, the impact of different ESBL genotypes of E. coli on the resistance to Cefepime (FEP) remains unc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544110/ https://www.ncbi.nlm.nih.gov/pubmed/37789844 http://dx.doi.org/10.2147/IDR.S427836 |
_version_ | 1785114432562528256 |
---|---|
author | Wu, Qian Shi, Jing Huang, Juan Gan, Delu Zhang, Lijun Li, Pu |
author_facet | Wu, Qian Shi, Jing Huang, Juan Gan, Delu Zhang, Lijun Li, Pu |
author_sort | Wu, Qian |
collection | PubMed |
description | BACKGROUND: Escherichia coli (E. coli) is a common pathogen in bloodstream infections (BSI), and the production of extended-spectrum beta-lactamases (ESBLs) is its main mechanism of resistance. However, the impact of different ESBL genotypes of E. coli on the resistance to Cefepime (FEP) remains unclear. METHODS: A total of 2356 cases of BSI patients were collected. The experimental group included 188 ESBL-positive E. coli strains that were resistant to FEP but sensitive to ceftazidime (CAZ). Antibiotic usage and resistance rates were evaluated through antimicrobial susceptibility testing and antibiotic usage records. The ESBL genotypes were identified, and the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of FEP were determined. RESULTS: In ESBL-positive E. coli, three ESBL genotypes were identified: 188 strains of CTX-M, 130 strains of TEM-1, and 26 strains of OXA-10. Among them, 124 strains carried both CTX-M-9 and TEM-1 genotypes, 22 strains carried two CTX-M genotypes (CTX-M-1 and CTX-M-2), 20 strains carried both CTX-M-9 and OXA-10, and 6 strains carried three genotypes (CTX-M-9, CTX-TEM-1, and OXA-10). The MIC50, MIC90, MPC50, and MPC90 of the 188 ESBL-positive E. coli were 64, 256, 128, and 528, respectively. The MIC values ranged from 32 to 256, while the MPC values ranged from 64 to 528. The MIC50, MIC90, MPC50, and MPC90 of the 40 ESBL-negative E. coli were 0.5, 1, 64, and 128, respectively; the MIC values ranged from 0.25 to 4, while the MPC values ranged from 32 to 256, respectively. CONCLUSION: ESBL-positive E. coli induces an increase in the MIC value of FEP, leading to an increase in FEP resistance. The inoculation effect also causes a significant increase in the MPC value of FEP, especially the increase in selection index value, indicating selective enrichment and amplification of drug-resistant mutants, resulting in clinical treatment failure. |
format | Online Article Text |
id | pubmed-10544110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105441102023-10-03 The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment Wu, Qian Shi, Jing Huang, Juan Gan, Delu Zhang, Lijun Li, Pu Infect Drug Resist Original Research BACKGROUND: Escherichia coli (E. coli) is a common pathogen in bloodstream infections (BSI), and the production of extended-spectrum beta-lactamases (ESBLs) is its main mechanism of resistance. However, the impact of different ESBL genotypes of E. coli on the resistance to Cefepime (FEP) remains unclear. METHODS: A total of 2356 cases of BSI patients were collected. The experimental group included 188 ESBL-positive E. coli strains that were resistant to FEP but sensitive to ceftazidime (CAZ). Antibiotic usage and resistance rates were evaluated through antimicrobial susceptibility testing and antibiotic usage records. The ESBL genotypes were identified, and the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of FEP were determined. RESULTS: In ESBL-positive E. coli, three ESBL genotypes were identified: 188 strains of CTX-M, 130 strains of TEM-1, and 26 strains of OXA-10. Among them, 124 strains carried both CTX-M-9 and TEM-1 genotypes, 22 strains carried two CTX-M genotypes (CTX-M-1 and CTX-M-2), 20 strains carried both CTX-M-9 and OXA-10, and 6 strains carried three genotypes (CTX-M-9, CTX-TEM-1, and OXA-10). The MIC50, MIC90, MPC50, and MPC90 of the 188 ESBL-positive E. coli were 64, 256, 128, and 528, respectively. The MIC values ranged from 32 to 256, while the MPC values ranged from 64 to 528. The MIC50, MIC90, MPC50, and MPC90 of the 40 ESBL-negative E. coli were 0.5, 1, 64, and 128, respectively; the MIC values ranged from 0.25 to 4, while the MPC values ranged from 32 to 256, respectively. CONCLUSION: ESBL-positive E. coli induces an increase in the MIC value of FEP, leading to an increase in FEP resistance. The inoculation effect also causes a significant increase in the MPC value of FEP, especially the increase in selection index value, indicating selective enrichment and amplification of drug-resistant mutants, resulting in clinical treatment failure. Dove 2023-09-27 /pmc/articles/PMC10544110/ /pubmed/37789844 http://dx.doi.org/10.2147/IDR.S427836 Text en © 2023 Wu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wu, Qian Shi, Jing Huang, Juan Gan, Delu Zhang, Lijun Li, Pu The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment |
title | The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment |
title_full | The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment |
title_fullStr | The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment |
title_full_unstemmed | The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment |
title_short | The Impact of ESBLs-Positive Escherichia coli’s Resistance to Cefepime and Its Guidance for Clinical Treatment |
title_sort | impact of esbls-positive escherichia coli’s resistance to cefepime and its guidance for clinical treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544110/ https://www.ncbi.nlm.nih.gov/pubmed/37789844 http://dx.doi.org/10.2147/IDR.S427836 |
work_keys_str_mv | AT wuqian theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT shijing theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT huangjuan theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT gandelu theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT zhanglijun theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT lipu theimpactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT wuqian impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT shijing impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT huangjuan impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT gandelu impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT zhanglijun impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment AT lipu impactofesblspositiveescherichiacolisresistancetocefepimeanditsguidanceforclinicaltreatment |